Brian Park, PharmD

Drug Information Specialist https://www.empr.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Drugs in the Pipeline

Epidiolex Gets Priority Review for Tuberous Sclerosis Complex-Associated Seizures

Brian Park, PharmD

April 2, 2020

The FDA has accepted for Priority Review the supplemental New Drug Application for Epidiolex.

Safety Alerts and Recalls

FDA: All Ranitidine Products Must Be Removed From the Market

Brian Park, PharmD

April 1, 2020

According to the results of tests conducted by the Agency, NDMA levels in ranitidine products can increase over time under normal storage conditions.

News

FDA Clears Hand-Held Vagus Nerve Stimulator for Migraine Prevention

Brian Park, PharmD

April 1, 2020

The FDA has approved an expanded indication for the gammaCore device to include prevention of migraine.

Drugs in the Pipeline

Dapagliflozin CKD Trial Stopped Early Due to “Overwhelming Efficacy”

Brian Park, PharmD

April 1, 2020

The decision to stop the trial was made based on positive efficacy data following a recommendation from the study’s independent DMC.

Drugs in the Pipeline

Significant Reduction in Monthly Migraine Days Observed With Rimegepant in Prevention Trial

Brian Park, PharmD

March 31, 2020

Biohaven announced positive topline results from a pivotal phase 2/3 study evaluating rimegepant for the preventive treatment of episodic and chronic migraine in adults.

News

Zerviate Ophthalmic Solution Now Available for Allergic Conjunctivitis

Brian Park, PharmD

March 31, 2020

Eyevance announced the launch of Zerviate™ (cetirizine ophthalmic solution) 0.24% for the treatment of ocular itching associated with allergic conjunctivitis in patients 2 years of age and older.

Drugs in the Pipeline

Study Shows Evolocumab Significantly Reduces LDL-C in Adults With HIV

Brian Park, PharmD

March 31, 2020

“This is the first phase 3 study to demonstrate that a PCSK9 inhibitor can effectively and safely reduce LDL-C in people living with HIV at risk for cardiovascular disease who have high cholesterol level despite statin treatment,” said Professor Franck Boccara, MD, PhD, cardiologist and primary study investigator.

Drugs in the Pipeline

Rivaroxaban Plus Aspirin Beneficial in Symptomatic PAD After Revascularization

Brian Park, PharmD

March 30, 2020

Xarelto, a Factor Xa inhibitor, is currently indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

News

Triferic AVNU Approved for Iron Replacement and Hemoglobin Maintenance in Dialysis Patients

Brian Park, PharmD

March 30, 2020

The FDA has approved the New Drug Application for Triferic AVNU®.

News

Taltz Approved for Pediatric Patients with Moderate to Severe Plaque Psoriasis

Brian Park, PharmD

March 27, 2020

The FDA has approved the supplemental Biologics License Application (sBLA) for Taltz (ixekizumab: Lilly) injection for the treatment of pediatric patients aged ≥6 years with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.